MAT1A and metabolic dysfunction-associated steatotic liver disease: Likewise, decreased circulating levels of α2AP have been associated with advanced liver fibrosis in two studies characterizing the plasma proteome in NAFLD patients and controls [9, 43], and decreased plasma concentrations of SAM and hepatic expression levels of MAT1A have been associated with NAFLD and/or liver fibrosis [12, 44, 45].